
NTC stands for Novelty, Technology, Care.
NTC is a R&D driven pharmaceutical company that develops products on initiative or on request on a global level with Headquarters in Milan, Italy.
Our portfolio of products is made of drugs, nutraceuticals and medical devices. We are now investing significantly in R&D and our pipeline is getting richer in particular areas like Ophthalmology, Gastrometabolism, Pediatrics, and Gyneacology.
Technology is a key part of our strategy. By working in partnership with qualified CMOs/CDMOs who are primarily located in the EU, we access and leverage many different technologies.
The company currently sells to licensees and distributors in nearly 100 countries to more than 200 companies.
Dedicated to creating sustainable value, NTC has integrated social and environmental considerations into its business operations and into its dealings with stakeholders. As part of its commitment to Corporate Social Responsibility, NTC has embedded international guidelines and procedures in its processes and practices.
NTC strongly believes in meritocracy and has created a challenging and stimulating work environment with a focus on transparency, listening culture and excellent employee benefits, resulting in outstanding employee performance and deep engagement. NTC focuses on building a productive
environment where accountability and mutual respect thrive and combine
to build a great place to work, while enabling the organization better to serve
and communicate with our customers.
Diversity is embedded in our history. We are involved in sustaining local communities, promoting diversity, and respecting our employees.
In terms of financial performance, we have consistently achieved, year after year, doubledigit top- and bottom-line growth in recent past, and, together with our business partners, we look forward to accelerate our pace of growth by rolling out new products.
NTC is a R&D driven pharmaceutical company that develops products on initiative or on request on a global level with Headquarters in Milan, Italy.
Our portfolio of products is made of drugs, nutraceuticals and medical devices. We are now investing significantly in R&D and our pipeline is getting richer in particular areas like Ophthalmology, Gastrometabolism, Pediatrics, and Gyneacology.
Technology is a key part of our strategy. By working in partnership with qualified CMOs/CDMOs who are primarily located in the EU, we access and leverage many different technologies.
The company currently sells to licensees and distributors in nearly 100 countries to more than 200 companies.
Dedicated to creating sustainable value, NTC has integrated social and environmental considerations into its business operations and into its dealings with stakeholders. As part of its commitment to Corporate Social Responsibility, NTC has embedded international guidelines and procedures in its processes and practices.
NTC strongly believes in meritocracy and has created a challenging and stimulating work environment with a focus on transparency, listening culture and excellent employee benefits, resulting in outstanding employee performance and deep engagement. NTC focuses on building a productive
environment where accountability and mutual respect thrive and combine
to build a great place to work, while enabling the organization better to serve
and communicate with our customers.
Diversity is embedded in our history. We are involved in sustaining local communities, promoting diversity, and respecting our employees.
In terms of financial performance, we have consistently achieved, year after year, doubledigit top- and bottom-line growth in recent past, and, together with our business partners, we look forward to accelerate our pace of growth by rolling out new products.
Location: Italy, Lombardy, Milan
Employees: 51-200
Founded date: 2017
Investors 1
Date | Name | Website |
- | Wise Equit... | wisesgr.co... |
Mentions in press and media 3
Date | Title | Description |
05.12.2024 | NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis | MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferi... |
07.10.2024 | NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE | MILAN, Oct. 7, 2024 /PRNewswire/ -- NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems, a global leading supplier of dispensing... |
19.04.2022 | Gastroenterology: NTC submits marketing authorisation application for KLEERKOL® in EU | MILAN, April 19, 2022 /PRNewswire/ -- NTC Srl, R&D driven pharmaceutical company with headquarters in Italy announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its d... |